

DELUCCA JOHN  
Form 4  
March 16, 2011

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
DELUCCA JOHN

2. Issuer Name and Ticker or Trading Symbol  
ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O ENDO PHARMACEUTICALS HOLDINGS INC., 100 ENDO BOULEVARD

03/14/2011

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

CHADDS FORD, PA 19317

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)	
				(A) or (D)	Price			
				Code	V	Amount		
2010 Stock Incentive Plan Restricted Stock Units (RSU) <sup>(1)</sup> <sup>(2)</sup>	03/14/2011		A	4,260	A	<u>(3)</u>	4,260	D
Common Stock, par value, \$.01 per share	03/14/2011		M	2,009	A	<u>\$ 0</u> <u>(4)</u>	16,115 <sup>(5)</sup>	D

Common Stock, par value, \$.01 per share      03/14/2011      M      1,417      A      \$ 0 <sup>(6)</sup>      16,115 <sup>(5)</sup>      D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
2007 Stock Incentive Plan Restricted Stock Units (RSU)	<u>(1)</u>	03/14/2011		M	2,009	03/14/2011 03/14/2011 <sup>(7)</sup>	Common Stock	2,009
2007 Stock Incentive Plan Restricted Stock Units (RSU)	<u>(1)</u>	03/14/2011		M	1,417	03/14/2011 03/14/2011 <sup>(8)</sup>	Common Stock	1,417

## Reporting Owners

Reporting Owner Name / Address

Relationships

Director    10% Owner    Officer    Other

DELUCCA JOHN  
C/O ENDO PHARMACEUTICALS HOLDINGS INC. X  
100 ENDO BOULEVARD  
CHADDS FORD, PA 19317

## Signatures

/s/ Caroline B. Manogue, by Power of Attorney 03/16/2011

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
- (2) These restricted stock units (RSUs) generally vest 100% on March 14, 2012. Upon vesting, we consider the underlying RSUs to be expired.
- (3) These securities were granted to Mr. Delucca in consideration of his services on the Endo Pharmaceuticals Holdings Inc. Board of Directors.
- (4) This represents vesting of restricted stock units granted to Mr. Delucca on March 12, 2009. Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.  
This number represents (i) 5,677 restricted stock units (including the 4,260 restricted stock units granted above) (ii) 2,262 shares of restricted stock, all of which are fully vested and (iii) 8,176 shares of common stock. Mr. Delucca's beneficial ownership disclosed in this table excludes all shares held by Mr. Delucca indirectly, including shares underlying stock options.
- (6) This represents vesting of restricted stock units granted to Mr. Delucca on March 12, 2010. Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.  
Fifty percent (50%) of Mr. Delucca's March 12, 2009 grant of restricted stock units (RSUs) generally vest on each of March 12, 2010 and
- (7) March 12, 2011. The 2,009 shown here is the amount that vested on March 14, 2011 (since March 12, 2012 was a Saturday). Upon vesting, we consider the underlying RSUs to be expired.  
Fifty percent (50%) of Mr. Delucca's March 12, 2010 grant of restricted stock units (RSUs) generally vest on each of March 12, 2011 and
- (8) March 12, 2012. The 1,417 shown here is the amount that vested on March 14, 2011 (since March 12, 2011 was a Saturday). Upon vesting, we consider the underlying RSUs to be expired.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.